Market news

CONMED's BioBrace and AirSeal platforms, robotic growth and easing supply bottlenecks support its long-term outlook despite tariff headwinds.

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LARGO, Fla., August 26, 2026--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA.

Recently, CONMED Corporation was highlighted for its positioning in differentiated surgical platforms such as AirSeal, Buffalo Filter, and BioBrace, with these products benefiting from supportive regulatory trends and growing clinical adoption, while the company continues to face risks from tariffs and slower expansion in specific platforms like AirSeal. An interesting angle is that regulatory momentum around operating room air quality and clinician willingness to adopt newer biomaterials...

What Is Driving Fresh Interest In CONMED Stock Today CONMED (CNMD) is back in focus as investors assess the adoption of its AirSeal, Buffalo Filter, and BioBrace platforms, along with tariff headwinds and slower AirSeal growth, in the context of the company’s broader earnings profile. See our latest analysis for CONMED. CONMED’s share price has moved to US$49.25 after a strong 30 day share price return of 14% and a 90 day share price return of 36.12%. However, the 1 year total shareholder...

CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.

CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.

CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.

Detailed price information for Sherwin-Williams Company (SHW-N) from The Globe and Mail including charting and trades.

Shares of medical tech company CONMED (NYSE:CNMD) jumped 10.5% in the afternoon session after the company reported second-quarter adjusted earnings that beat analyst expectations and raised its full-year guidance.

CONMED (CNMD) reported Q2 adjusted earnings late Wednesday of $1.38 per diluted share, up from $1.15

CNMD's Q2 earnings and revenues beat estimates, while margin growth and solid international sales support a higher 2026 EPS outlook.

Medical tech company CONMED (NYSE:CNMD) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales were flat year on year at $343.5 million. The company expects the full year’s revenue to be around $1.37 billion, close to analysts’ estimates. Its non-GAAP profit of $1.38 per share was 24.3% above analysts’ consensus estimates.

Conmed (CNMD) delivered earnings and revenue surprises of +25.46% and +1.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

CONMED (NYSE:CNMD) reported second-quarter 2026 net sales of $343.5 million, up 0.3% on a reported basis but down 0.5% in constant currency. Organic sales, which exclude the company’s exited gastroenterology product offerings, rose 6% year over year and modestly exceeded management’s expectations.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

LARGO, Fla., July 29, 2026--CONMED Corporation (NYSE: CNMD) today reported financial results for the second quarter ended June 30, 2026 and updated its financial guidance for the full year ending 2026.

Medical tech company CONMED (NYSE:CNMD) will be reporting results this Wednesday after market close. Here’s what investors should know.

Detailed price information for C O N M E D Corp (CNMD-N) from The Globe and Mail including charting and trades.

Conference spotlight and why CONMED stock is on watch CONMED (CNMD) is in focus as the company prepares for its presentation at the SRS Annual Meeting, where consultant urological surgeons Amit Taggar and Nikhil Vasdev are scheduled to speak on July 24, 2026. See our latest analysis for CONMED. Beyond the conference appearance, CONMED’s share price has recently picked up, with a 30 day share price return of 18.72% and a 90 day gain of 12.70%. However, the 1 year total shareholder return is...

CNMD's FDA-expanded AirSeal indication adds da Vinci 5 hex cannula compatibility, supporting broader use across Intuitive Surgical's robotic systems.

LARGO, Fla., July 22, 2026--CONMED Corporation (NYSE: CNMD) today announced that its AirSeal® Robotic Solution is now indicated for use with Intuitive’s 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform ("dV5"). Alongside its existing indication for Intuitive 8 mm round cannulas, the AirSeal Robotic Solution now has an expanded indication for use across Intuitive’s portfolio of da Vinci X, da Vinci Xi, and da Vinci 5 robotic systems.

LARGO, Fla., July 20, 2026--CONMED Corporation (NYSE: CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL.

On Friday, a Bloomberg Law report indicated that the company is considering a sale after private equity investors expressed interest.

Shares of medical tech company CONMED (NYSE:CNMD) jumped 9% in the afternoon session after reports revealed the company is exploring a potential sale.

The medical technology company is working with advisers to evaluate strategic options, Bloomberg Law reported, citing people familiar with the matter.

CONMED is under fresh scrutiny after the modeled fair value estimate was reduced from US$48.40 to US$39.60, aligning more closely with a US$40 price target cited in recent research. Several analysts have turned more cautious, revisiting where that US$40 level fits against revised growth expectations and how the stock compares with larger medtech peers. As you read on, you will see what is driving these shifts and how to follow the evolving narrative around CONMED. Stay updated as the Fair...